Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries.
epidemiology
respiratory syncytial virus
seasonality
surveillance
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
01
06
2021
accepted:
14
06
2021
pubmed:
14
7
2021
medline:
26
11
2021
entrez:
13
7
2021
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) infections are one of the leading causes of lower respiratory tract infections and have a major burden on society. For prevention and control to be deployed effectively, an improved understanding of the seasonality of RSV is necessary. The main objective of this study was to contribute to a better understanding of RSV seasonality by examining the GERi multi-country surveillance dataset. RSV seasons were included in the analysis if they contained ≥100 cases. Seasonality was determined using the "average annual percentage" method. Analyses were performed at a subnational level for the United States and Brazil. We included 601 425 RSV cases from 12 countries. Most temperate countries experienced RSV epidemics in the winter, with a median duration of 10-21 weeks. Not all epidemics fit this pattern in a consistent manner, with some occurring later or in an irregular manner. More variation in timing was observed in (sub)tropical countries, and we found substantial differences in seasonality at a subnational level. No association was found between the timing of the epidemic and the dominant RSV subtype. Our findings suggest that geographical location or climatic characteristics cannot be used as a definitive predictor for the timing of RSV epidemics and highlight the need for (sub)national data collection and analysis.
Sections du résumé
BACKGROUND
Respiratory syncytial virus (RSV) infections are one of the leading causes of lower respiratory tract infections and have a major burden on society. For prevention and control to be deployed effectively, an improved understanding of the seasonality of RSV is necessary.
OBJECTIVES
The main objective of this study was to contribute to a better understanding of RSV seasonality by examining the GERi multi-country surveillance dataset.
METHODS
RSV seasons were included in the analysis if they contained ≥100 cases. Seasonality was determined using the "average annual percentage" method. Analyses were performed at a subnational level for the United States and Brazil.
RESULTS
We included 601 425 RSV cases from 12 countries. Most temperate countries experienced RSV epidemics in the winter, with a median duration of 10-21 weeks. Not all epidemics fit this pattern in a consistent manner, with some occurring later or in an irregular manner. More variation in timing was observed in (sub)tropical countries, and we found substantial differences in seasonality at a subnational level. No association was found between the timing of the epidemic and the dominant RSV subtype.
CONCLUSIONS
Our findings suggest that geographical location or climatic characteristics cannot be used as a definitive predictor for the timing of RSV epidemics and highlight the need for (sub)national data collection and analysis.
Identifiants
pubmed: 34255934
doi: 10.1111/irv.12885
pmc: PMC8542954
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
732-741Informations de copyright
© 2021 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409569
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):71-76
pubmed: 29346336
Influenza Other Respir Viruses. 2021 Nov;15(6):732-741
pubmed: 34255934
Mem Inst Oswaldo Cruz. 2016 May;111(5):294-301
pubmed: 27120006
PLoS One. 2016 Mar 31;11(3):e0152310
pubmed: 27031105
Epidemiol Infect. 2007 Oct;135(7):1077-90
pubmed: 17346359
Epidemiol Infect. 2020 Feb 13;148:e48
pubmed: 32052719
Influenza Other Respir Viruses. 2021 Jan;15(1):56-63
pubmed: 32656961
J Clin Virol. 2019 Nov;120:68-77
pubmed: 31590113
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583
pubmed: 30880339
Influenza Other Respir Viruses. 2020 Nov;14(6):638-646
pubmed: 32163226
Int J Infect Dis. 2018 Oct;75:18-25
pubmed: 30118916
Epidemiol Infect. 1998 Aug;121(1):121-8
pubmed: 9747763
PLoS One. 2016 Apr 27;11(4):e0153003
pubmed: 27119988
Emerg Infect Dis. 2021 May;27(5):1537-1540
pubmed: 33900190
Pediatr Infect Dis J. 2009 Oct;28(10):860-6
pubmed: 20118684
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S21-32
pubmed: 12671449
Open Forum Infect Dis. 2021 Mar 30;8(7):ofab159
pubmed: 34337092
Euro Surveill. 2019 May;24(20):
pubmed: 31115311
Ther Adv Infect Dis. 2016 Apr;3(2):63-71
pubmed: 27034777
Lancet Infect Dis. 2018 Oct;18(10):e295-e311
pubmed: 29914800
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
Microorganisms. 2020 May 11;8(5):
pubmed: 32403364
J Infect Dis. 2013 Dec 15;208 Suppl 3:S246-54
pubmed: 24265484
Sci Data. 2018 Oct 30;5:180214
pubmed: 30375988
PLoS One. 2013;8(2):e54445
pubmed: 23457451
PLoS Pathog. 2015 Jan 08;11(1):e1004591
pubmed: 25569275
Emerg Infect Dis. 2019 Jun;25(6):1127-1135
pubmed: 31107230
Lancet Glob Health. 2019 Aug;7(8):e1031-e1045
pubmed: 31303294
J Infect Dis. 2018 Apr 11;217(9):1356-1364
pubmed: 29390105
J Infect. 2019 Oct;79(4):373-382
pubmed: 31323249
J Glob Health. 2019 Dec;9(2):020431
pubmed: 31893034